Genfit - die Alternative zu Intercept? (Seite 27)
eröffnet am 15.09.14 19:22:45 von
neuester Beitrag 20.12.23 20:39:08 von
neuester Beitrag 20.12.23 20:39:08 von
Beiträge: 408
ID: 1.199.217
ID: 1.199.217
Aufrufe heute: 0
Gesamt: 52.657
Gesamt: 52.657
Aktive User: 0
ISIN: FR0004163111 · WKN: A0LGJ2 · Symbol: XUP
3,1700
EUR
-1,40 %
-0,0450 EUR
Letzter Kurs 25.04.24 Tradegate
Neuigkeiten
25.04.24 · globenewswire  |
15.04.24 · globenewswire |
05.04.24 · globenewswire |
04.04.24 · globenewswire |
29.02.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 0,5250 | +19,08 | |
| 5,8900 | +17,80 | |
| 1,9700 | +15,20 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,8150 | -15,21 | |
| 3,0400 | -19,95 | |
| 1,9500 | -25,14 | |
| 2,2600 | -30,25 | |
| 0,5121 | -30,80 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 49.002.008 von asw22 am 06.02.15 17:14:14bis zu den Resultaten im März wird es hier noch Möglichkeiten geben, hoffe ich.
Irgendwann muss die ja nochmal konsolidieren, so ganz durch ist sie noch nicht durch die 60.
Ich hoffe nächste Woche geht es nochmal bergab, in die tiefen 50er.
Irgendwann muss die ja nochmal konsolidieren, so ganz durch ist sie noch nicht durch die 60.
Ich hoffe nächste Woche geht es nochmal bergab, in die tiefen 50er.
Ich glaub ich bin hier zu früh raus *seufz* ;-)
Antwort auf Beitrag Nr.: 48.996.623 von question-mark am 06.02.15 09:53:00PCB allein rechtfertigt die Mk von 4mrd$ sicherlich nicht.
Nash Blockbuster wird ein vielfaches wert sein.
nmM
http://www.thestreet.mobi/story/12530749/1/intercept-pharma-drug-scores-pivotal-study-win-against-rare-liver-disease.html
Intercept will ask the FDA to approve OCA for patients with PBC who are not responding to, or cannot tolerate, ursodiol, a drug used to treat the disease for the past two decades. The company believes the primary endpoint of the POISE study -- reductions in the harmful liver enzyme ALP -- is strong enough to get the drug approved on an accelerated basis, although FDA has not yet signaled agreement. If OCA is granted accelerated approval, Intercept will be required to conduct a post-marketing study to confirm the drug's efficacy, likely using a more definitive endpoint like reduction in liver transplant or death.
The company has clinical data from a registry of 6,000 PBC patients showing reductions in ALP reduce the risk of liver transplant and death.
Intercept believes there are approximately 30,000 people in developed countries with PBC who would be eligible for treatment with OCA, if approved.
Nash Blockbuster wird ein vielfaches wert sein.
nmM
http://www.thestreet.mobi/story/12530749/1/intercept-pharma-drug-scores-pivotal-study-win-against-rare-liver-disease.html
Intercept will ask the FDA to approve OCA for patients with PBC who are not responding to, or cannot tolerate, ursodiol, a drug used to treat the disease for the past two decades. The company believes the primary endpoint of the POISE study -- reductions in the harmful liver enzyme ALP -- is strong enough to get the drug approved on an accelerated basis, although FDA has not yet signaled agreement. If OCA is granted accelerated approval, Intercept will be required to conduct a post-marketing study to confirm the drug's efficacy, likely using a more definitive endpoint like reduction in liver transplant or death.
The company has clinical data from a registry of 6,000 PBC patients showing reductions in ALP reduce the risk of liver transplant and death.
Intercept believes there are approximately 30,000 people in developed countries with PBC who would be eligible for treatment with OCA, if approved.
Antwort auf Beitrag Nr.: 48.986.975 von question-mark am 05.02.15 12:34:35
... das mit unter 50 Euro kann ich wohl vergessen
Zitat von question-mark: Genfit will einach nicht so weit runter wie ich das gerne hätte, eignentlich möchte ich wieder aufstocken, aber bitte unter 5o Euro
... das mit unter 50 Euro kann ich wohl vergessen
Antwort auf Beitrag Nr.: 48.993.827 von hico am 05.02.15 21:21:31hab mir jetzt mal Intercept angesehen, die Bewertung ist natürlich üppig (Tendenz zur Fettleber...)
Wie gross ist denn der PCB Markt im Vergleich zu NASH? Ich überlege nun doch, auf beide Pferde zu setzen ...
Wie gross ist denn der PCB Markt im Vergleich zu NASH? Ich überlege nun doch, auf beide Pferde zu setzen ...
Trading Spotlight
Antwort auf Beitrag Nr.: 48.986.975 von question-mark am 05.02.15 12:34:35Der Lauch ist 2016 reif - und er soll ja auch bei Fettleber helfen
http://www.medizinauskunft.de/artikel/diagnose/krankheiten/M…
Launch 2016 bezieht sich auf die Zulassung von OCA in PCB nicht Nash. Dort ist man ja mitten in PIII. Denke das ist realistisch.
http://www.medizinauskunft.de/artikel/diagnose/krankheiten/M…
Launch 2016 bezieht sich auf die Zulassung von OCA in PCB nicht Nash. Dort ist man ja mitten in PIII. Denke das ist realistisch.
Intercept Pharmaceuticals Announces Pricing of Public Offering
today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $176.00 per share. In addition, Intercept has granted the underwriters a 30-day option to purchase up to an additional 150,000 shares of common stock.
All shares in the offering are being sold by Intercept, with expected net proceeds to Intercept of approximately $166.2 million (or approximately $191.2 million if the underwriters exercise in full their option to purchase additional shares), after deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on or about February 10, 2015, subject to customary closing conditions.
http://finance.yahoo.com/news/intercept-pharmaceuticals-anno…
Citigroup, RBC Capital Markets and Deutsche Bank Securities are acting as joint book-running managers and underwriters for the offering. BMO Capital Markets is acting as lead manager and Nomura, Wedbush PacGrow Life Sciences, JMP Securities, Needham & Company, Oppenheimer & Co. and Summer Street Research Partners are acting as co-managers.
today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $176.00 per share. In addition, Intercept has granted the underwriters a 30-day option to purchase up to an additional 150,000 shares of common stock.
All shares in the offering are being sold by Intercept, with expected net proceeds to Intercept of approximately $166.2 million (or approximately $191.2 million if the underwriters exercise in full their option to purchase additional shares), after deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on or about February 10, 2015, subject to customary closing conditions.
http://finance.yahoo.com/news/intercept-pharmaceuticals-anno…
Citigroup, RBC Capital Markets and Deutsche Bank Securities are acting as joint book-running managers and underwriters for the offering. BMO Capital Markets is acting as lead manager and Nomura, Wedbush PacGrow Life Sciences, JMP Securities, Needham & Company, Oppenheimer & Co. and Summer Street Research Partners are acting as co-managers.
ICPT will den lauch in 2016, und gleich in EU mit?
wusste gar nicht , dass die so weit sind, oder ist das sehr sportlich, was die melden?
Genfit will einach nicht so weit runter wie ich das gerne hätte, eignentlich möchte ich wieder aufstocken, aber bitte unter 5o Euro
wusste gar nicht , dass die so weit sind, oder ist das sehr sportlich, was die melden?
Genfit will einach nicht so weit runter wie ich das gerne hätte, eignentlich möchte ich wieder aufstocken, aber bitte unter 5o Euro
800000stk sind ca 3,8% plus ggf 120000stk
Für mich hört sich das nicht so schlimm an. Der markt hats auch so aufgenommen.
Wenn dies geschickt anstellen nehmen die 920000stk x 300$ = 276mio$ ein
sollte dann ne weile langen.
that it has commenced an underwritten public offering of 800,000 shares of its common stock. All of the shares in the offering are to be sold by Intercept.
Citigroup and RBC Capital Markets are acting as joint book-running managers for the proposed offering. Intercept intends to grant the underwriters a 30-day option to purchase up to an additional 120,000 shares of common stock on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Intercept intends to use the net proceeds of this offering to support the expansion of its clinical, regulatory, medical affairs and commercial infrastructure in the United States and Europe, the clinical development program for obeticholic acid (OCA) in primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), the expansion of OCA manufacturing activities, advancement of INT-767 and other preclinical pipeline programs, and the preparation for and potential initiation of the commercial launch of OCA in PBC in the United States and certain European countries in 2016. The balance, if any, will be used for general corporate purposes.
Für mich hört sich das nicht so schlimm an. Der markt hats auch so aufgenommen.
Wenn dies geschickt anstellen nehmen die 920000stk x 300$ = 276mio$ ein
sollte dann ne weile langen.that it has commenced an underwritten public offering of 800,000 shares of its common stock. All of the shares in the offering are to be sold by Intercept.
Citigroup and RBC Capital Markets are acting as joint book-running managers for the proposed offering. Intercept intends to grant the underwriters a 30-day option to purchase up to an additional 120,000 shares of common stock on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Intercept intends to use the net proceeds of this offering to support the expansion of its clinical, regulatory, medical affairs and commercial infrastructure in the United States and Europe, the clinical development program for obeticholic acid (OCA) in primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), the expansion of OCA manufacturing activities, advancement of INT-767 and other preclinical pipeline programs, and the preparation for and potential initiation of the commercial launch of OCA in PBC in the United States and certain European countries in 2016. The balance, if any, will be used for general corporate purposes.
Antwort auf Beitrag Nr.: 48.973.790 von question-mark am 04.02.15 11:31:02http://m.seekingalpha.com/news/2270076?source=ansh
Durchsuchen
